Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2020

Mar 27, 2020

33148_dirs_2020-03-26_536566e1-32c1-4aeb-bce9-25bc0e2682a8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2020-03-24

Reporting Person: Shah Gaurav (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-03-24 Common Stock M 90925 $0.43 Acquired 1061642 Direct
2020-03-24 Common Stock F 32645 $13.78 Disposed 1028997 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-03-24 Stock Option (Right to Buy) $0.44 M 90925 Disposed 2020-12-15 Common Stock (90925) Direct

Footnotes

F1: The options exercised and reported on this Form 4 were required to be exercised or otherwise forfeited in 2020 due to their upcoming expiration.

F2: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price and the tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of on this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer to cover the exercise price of the options and the tax liability,

F3: The option is fully vested and immediately exercisable and will expire under its own terms this year.